Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 992.0498 INR -1.32% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Divi's Laboratories Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Divi's Laboratories Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Divi's Laboratories Ltd
NSE:DIVISLAB
Note Receivable
â‚ą1.3B
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Note Receivable
â‚ą59k
CAGR 3-Years
N/A
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Note Receivable
â‚ą1.6B
CAGR 3-Years
-8%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Note Receivable
â‚ą2.1B
CAGR 3-Years
32%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Tarsons Products Ltd
NSE:TARSONS
Note Receivable
â‚ą42.2m
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Note Receivable
â‚ą7.3m
CAGR 3-Years
-18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. is a prominent player in the pharmaceutical industry, primarily known for its role as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990, the company has established a robust reputation for its high-quality products and commitment to research and development. With an extensive product portfolio that serves a multitude of therapeutic areas, including pain management, oncology, and cardiovascular treatments, Divi's has positioned itself as a trusted partner to both domestic and global pharmaceutical companies. The company's state-of-the-art manufacturing facilities, compliant with international regulatory standards, ensure that it meets the growing demand for cost-effective and high-quality APIs, which is increasingly vital as the world turns to generics and specialty medicines. For investors, Divi's Laboratories presents a compelling opportunity anchored in its sustainable growth trajectory and financial resilience. Over the years, the company has demonstrated strong revenue growth and healthy profit margins, reflecting its operational efficiency and strategic focus on innovation. With a diversified customer base across more than 95 countries, the company is well-positioned to capitalize on emerging market trends and the ongoing expansion in global healthcare requirements. As healthcare systems evolve and the demand for affordable pharmaceuticals surges, Divi’s commitment to excellence and innovation keeps it at the forefront of the industry, making it an attractive investment for those looking to align with a company that not only generates value but also significantly contributes to global health outcomes.

DIVISLAB Intrinsic Value
2 928.8746 INR
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Divi's Laboratories Ltd's Note Receivable?
Note Receivable
1.3B INR

Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Note Receivable amounts to 1.3B INR.

What is Divi's Laboratories Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
1%

Over the last year, the Note Receivable growth was 339%. The average annual Note Receivable growth rates for Divi's Laboratories Ltd have been 1% over the past three years .

Back to Top